Purpose Of Review: Intraoperative floppy iris syndrome (IFIS) occurs in 2% of cataract surgeries and is associated with an increased risk of surgical complications. These complications can be avoided when high-risk patients are identified by preoperative screening and appropriate measures are used intraoperatively. The purpose of this article is to review emerging risk factors for IFIS and to summarize management strategies used in IFIS.
Recent Findings: Although α1-antagonists in general, and tamsulosin (Flomax, Jalyn) in particular, have long been associated with IFIS, recent studies have more firmly demonstrated the elevated risk of IFIS attributed to tamsulosin. This resulted in a revision of the American Society of Cataract and Refractive Surgery/American Academy of Ophthalmology guidelines on IFIS. Our understanding of additional medications and medical conditions involved in IFIS is also evolving, including an appreciation that women are also susceptible to IFIS. New modifications of techniques used in the intraoperative management of IFIS are also discussed.
Summary: Preoperative screening should include both men and women. Current or prior use of α1-antagonists and antipsychotics should be documented, along with hypertension. Surgeons should be prepared to employ a range of perioperative interventions in a graded response to IFIS of different severities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ICU.0000000000000322 | DOI Listing |
Curr Med Mycol
May 2024
Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.
Background And Purpose: Invasive candidiasis (IC) in the hospitalized population is one of the leading causes of invasive fungal infections (IFIs). Microbiological diagnosis of IC suffers due to poor sensitivity of blood culture and relative inaccessibility to more sensitive modalities. (1, 3)-β-D-glucan (BDG) is a cell wall polysaccharide found in a range of fungi.
View Article and Find Full Text PDFInfect Disord Drug Targets
December 2024
Indeus Life Sciences, Mumbai, Maharashtra, India.
Invasive fungal infections (IFIs) pose a significant global health threat, particularly among immunocompromised individuals. These infections can lead to severe illness and death, placing a significant financial burden on healthcare systems. Fungi were not previously considered a substantial risk to human health, but this perception changed with the rise of the HIV epidemic.
View Article and Find Full Text PDFJ Clin Med
November 2024
Department of Child Health, Sultan Qaboos University Hospital, University Medical City, Muscat 123, Oman.
Invasive fungal infections (IFIs) are a prevalent complication of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) in the pediatric population and are associated with high morbidity and mortality. We aimed to identify the utilization of antifungal prophylaxis prescriptions and the associated clinical outcomes. A retrospective study included children (≤18 years old) diagnosed with hematological malignancies or undergoing HSCT who are at high risk for developing IFI and received systemic antifungal therapy between January 2018 and April 2024 at Sultan Qaboos University Hospital (SQUH), Oman.
View Article and Find Full Text PDFInt J Clin Pharm
December 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Background: Posaconazole is widely recommended for preventing and treating invasive fungal infections (IFIs) in immunocompromised patients, especially those with prolonged neutropenia. However, the concentration of the oral suspension formulation can be affected by factors such as co-administration with acid-suppressing medications, influencing its efficacy and safety.
Aim: This study examined the impact of proton pump inhibitors (PPIs) and other factors on posaconazole concentrations and the concentration-to-dose ratio (C/D) while also evaluating adverse drug reactions in patients with hematologic malignancies.
Infect Dis Ther
November 2024
Universidade Federal do Paraná (UFPR), 181, General Carneiro Street, Curitiba, PR, Brazil.
Introduction: Amphotericin B lipid complex (ABLC) is an effective antifungal agent for treating invasive fungal infections (IFIs) even though its formulation is associated with potential adverse events, including those related to its infusion. This study aimed to analyze the incidence of acute infusion-related side effects (IRSE) associated with ABLC and their relationship with the profile of patients with oncohematological disease admitted in Brazilian reference tertiary hospitals.
Methods: This is an observational retrospective study that included clinical records of patients hospitalized, in a period of 6 years, diagnosed with probable or proved IFI and treated with at least two doses of ABLC.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!